ImmunoMRI for Assessment of Tumor-associated Macrophages

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

September 30, 2028

Conditions
DLBCL - Diffuse Large B Cell Lymphoma
Interventions
DRUG

MRI contrast-enhancing agents

"1. Ferumoxytol will be injected as an off-label MRI contrast agent at a dose of 4 mg/kg body mass. For safety (in accordance with prior research), ferumoxytol will be diluted 1:4 in saline, and administered slowly over at least 15 minutes, with patient monitoring during and post injection.~2. ImmunoMRI will be performed using an iron sensitive fat-suppressed, fast spoiled gradient echo T2\* mapping sequence. At each time point (i.e. pre-treatment and post-treatment), T2\* mapping will be performed before and \~24h after ferumoxytol injection."

Trial Locations (1)

1090

Medical University of Vienna, Vienna

All Listed Sponsors
lead

Medical University of Vienna

OTHER